Across TCGA pan-cancer cohorts, CCDC169 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CCDC169 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher CCDC169 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC169 expression acts as an unfavorable survival marker.
COAD are the cancer types where CCDC169 Mutation most reproducibly stratifies survival.